 |
|
|
| |
VIROLOGIC FAILURE AND RESISTANCE IN
DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS
|
| |
| |
Dolutegravir+3TC - 2 Drug ART at CROI
DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)
ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 Switch Study TANGO Through Week 48 (03/13/20)
EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR + LAMIVUDINE AS MAINTENANCE REGIMEN (03/30/20)
VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (03/30/20)
LONG-TERM DTG+3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE (03/30/20)
SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE (03/30/20)
EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL-LIFE (03/30/20)
CROI 2020
Reported by Jules Levin
Colin Deschanvres1, François Raffi1, Jacques Reynes2, Bruno Hoen3, David Rey4, RomainPalich5, Olivier Robineau6, FirouzeBani-Sadr7, Claudine Duvivier8, Laurent Hocqueloux9, LiseCuzin10, VeroniqueJoly11, Andre Cabie11, Clotilde Allavena1for the Dat'AIDSStudy Group
1CHU de Nantes, Nantes, France, 2CHU de Montpellier, Montpellier, France, 3CHRU de Nancy, Nancy, France, 4 HôpitauxUniversitairesde Strasbourg, Strasbourg, France, 5AP-HP HôpitauxUniversitairesPitie-Salpetriere, Paris, France, 5 Centre Hospitalierde Tourcoing, Tourcoing, France, 7CHU de Reims, Reims, France, 8AP-HP Necker Hospital, Paris, France, 9Centre HospitalierRegional, Orleans, France, 10CHU Fort de France, Martinique, France, 11AP-HP HôpitalBichat-Claude Bernard, Paris France
|
| |
|
|
|
|
|
